Sillman F H, Fruchter R G, Chen Y S, Camilien L, Sedlis A, McTigue E
Division of Gynecologic Oncology, State University of New York, Downstate Medical School, Brooklyn, USA.
Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):93-9. doi: 10.1016/s0002-9378(97)80018-x.
Our purpose was to profile patients with vaginal intraepithelial neoplasia, evaluate the response to treatment and define risk factors for persistence and progression.
We reviewed records and histopathology slides of 94 patients with vaginal intraepithelial neoplasia diagnosed from 1977 to 1986. For 74 patients with follow-up, we evaluated risk factors by univariate and multivariate analyses.
Sixty-four of 94 patients (68%) had prior or concurrent anogenital squamous neoplasia, including 21 with invasive and 43 with intraepithelial. Twenty-three had prior radiotherapy, 10 had anogenital neoplastic syndrome, and 11 were immunosuppressed. In 52 of 74 treated patients (70%), vaginal intraepithelial neoplasia went into remission after a single treatment. In 18 patients (70%) vaginal intraepithelial neoplasia went into remission after a single treatment. In 18 patients (24%) recurrent vaginal intraepithelial neoplasia went into remission after chemosurgery, upper vaginectomy, or other treatments; in 4 (5%) it progressed to invasion. Significant multivariate risk factors for persistence or progression were multifocal lesions and anogenital neoplastic syndrome but not vaginal intraepithelial neoplasia grade, associated cervical neoplasia, or immunosuppression.
Although most vaginal intraepithelial neoplasia goes into remission after treatment, 5% of cases may progress from occult foci to invasion in spite of close follow-up.
我们的目的是描述阴道上皮内瘤变患者的特征,评估治疗反应并确定持续存在和进展的风险因素。
我们回顾了1977年至1986年诊断为阴道上皮内瘤变的94例患者的记录和组织病理学切片。对于74例有随访资料的患者,我们通过单因素和多因素分析评估风险因素。
94例患者中有64例(68%)有既往或同时存在的肛门生殖器鳞状上皮瘤变,包括21例浸润性和43例上皮内瘤变。23例有既往放疗史,10例有肛门生殖器肿瘤综合征,11例免疫抑制。74例接受治疗的患者中有52例(70%)经单次治疗后阴道上皮内瘤变缓解。18例患者(70%)经单次治疗后阴道上皮内瘤变缓解。18例患者(24%)复发性阴道上皮内瘤变经化学手术、阴道上段切除术或其他治疗后缓解;4例(5%)进展为浸润癌。持续存在或进展的重要多因素风险因素是多灶性病变和肛门生殖器肿瘤综合征,而非阴道上皮内瘤变分级、相关宫颈肿瘤或免疫抑制。
尽管大多数阴道上皮内瘤变经治疗后缓解,但尽管密切随访,仍有5%的病例可能从隐匿病灶进展为浸润癌。